RBC Capital raised the firm’s price target on Amgen to $329 from $303 and keeps an Outperform rating on the shares. The analyst cites the company’s Q4 earnings beat while also noting the management’s “exceedingly positive posture” on obesity following MariTide’s phase 1 data publication and potential for larger program exploration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
